Jama Author Interviews: Covering Research In Medicine, Science, & Clinical Practice. For Physicians, Researchers, & Clinician

Valganciclovir is standard cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant recipients, but its use is limited by myelosuppression. JAMA Deputy Editor Preeti Malani, MD, MSJ, interviews Ajit Limaye, MD, from the University of Washington, about a multinational randomized trial of letermovir vs valganciclovir for CMV prevention in CMV-negative patients receiving a kidney from a CMV-positive donor. Related Content: Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients